Breaking Down SG&A Expenses: argenx SE vs United Therapeutics Corporation

A Comparative Analysis of SG&A Expenses: Argenx SE vs United Therapeutics Corporation

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Argenx SE and United Therapeutics Corporation from 2014 to 2023. Over this period, Argenx SE has shown a remarkable increase in SG&A expenses, growing from a modest $4.2 million in 2014 to an impressive $709 million in 2023. This represents a staggering growth of over 16,700%, reflecting Argenx's aggressive expansion and investment in its operations.

Conversely, United Therapeutics Corporation has maintained a more stable trajectory, with SG&A expenses fluctuating between $266 million and $487 million. This stability suggests a consistent operational strategy, focusing on steady growth and cost management. As the pharmaceutical industry continues to innovate, these financial insights provide a window into the strategic priorities of these two industry leaders.